Gossamer Bio, Inc.

Equities

GOSS

US38341P1021

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/05/2024 BST			5-day change	1st Jan Change
0.5945 ^USD	-4.10%		-11.27%	-34.85%

05-07	Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-06	Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	CI

Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 03, 2022 at 08:03 pm

Gossamer Bio, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 59.36 million compared to USD 60.25 million a year ago. Basic loss per share from continuing operations was USD 0.65 compared to USD 0.8 a year ago.
For the nine months, net loss was USD 173.61 million compared to USD 177.72 million a year ago. Basic loss per share from continuing operations was USD 2.14 compared to USD 2.38 a year ago.

Latest news about Gossamer Bio, Inc.

Gossamer Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Chiesi Farmaceutici S.P.A Gossamer Bio, Inc Announces Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications	05-06	CI
Transcript : Chiesi Farmaceutici S.p.A., Gossamer Bio, Inc. - M&A Call	05-06
Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment	05-06	RE
Gossamer Bio Announces Publication of Torrey Phase 2 Results in the Lancet Respiratory Medicine	05-03	CI
Transcript : Gossamer Bio, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM	03-13
Gossamer Bio Announces Board of Directors Appointments	03-12	CI
Goldman Sachs Adjusts Price Target on Gossamer Bio to $8 From $9, Maintains Buy Rating	03-06	MT
Gossamer Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Gossamer Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
HC Wainwright Adjusts Price Target on Gossamer Bio to $10 From $5, Keeps Buy Rating	01-08	MT
Transcript : Gossamer Bio, Inc. - Special Call	12-18
Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from NASDAQ Biotechnology Index	12-15	CI
Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer	12-05	CI
Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors	11-29	CI
Wedbush Lifts Gossamer Bio's PT to $6 From $5, Increases Multiple for Seralutinib for Pulmonary Arterial Hypertension in US, EU; Keeps Outperform Rating	11-10	MT
Gossamer Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Gossamer Bio, Inc. Announces Resignation of Kristina Burow from the Board of Directors	07/09/23	CI
Gossamer Bio, Inc. to Present Results of TORREY FRI Sub- Study At the European Respiratory Society International Congress 2023	07/09/23	CI
North American Morning Briefing : China Angst -2-	15/08/23	DJ
Gossamer Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Gossamer Bio, Inc. announced that it has received $211.849524 million in funding from a group of investors	06/08/23	CI
UBS Downgrades Gossamer Bio to Neutral From Buy, Adjusts Price Target to $1.25 From $8	27/07/23	MT
Wedbush Trims Gossamer Bio's Price Target to $5 From $7, Keeps Outperform Rating	26/07/23	MT
Transcript : Gossamer Bio, Inc. - Special Call	25/07/23

Chart Gossamer Bio, Inc.

Duration

Period

More charts

Company Profile

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, Î± and Î², as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.5945 USD

Average target price

6.094 USD

Spread / Average Target

+925.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GOSSAMER BIO, INC.	-34.85%	134M
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+40.01%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research